A phase 1/2 trial of ZL-1310 in advanced solid tumours, run by Zai Lab (Shanghai) Co., Ltd., now recruiting.
A Study of ZL-1310 in Participants With Selected Solid Tumors is a phase 1/2 interventional study registered as NCT06885281 by Zai Lab (Shanghai) Co., Ltd., with 166 participants planned, started 2025-05-12 and due to reach its primary completion in 2027-08. Interventions recorded: ZL-1310.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.